ETHZilla

ETHZilla Interest Expense

The Interest Expense of ETHZilla (ETHZ) as of Nov 17, 2026 is 141,500.00 USD. In the previous year, Interest Expense was 30,500.00 USD — a change of 363.93% (higher).

Interest Expense

141,500.00USD

YoY

363.93%

Last updated:

Interest Expense of ETHZilla is 2024 141,500.00 USD. Interest Expense of ETHZilla was 2023 30,500.00 USD. It decreases by 363.93% higher compared to the previous year.

The ETHZilla Interest Expense history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Interest Expense
Date
Interest Expense
Jan 1, 2017
663,000.00 USD
Jan 1, 2018
2.05 M USD
Jan 1, 2019
1.37 M USD
Jan 1, 2020
-2.90 M USD
Jan 1, 2021
-4.86 M USD
Jan 1, 2022
15.12 M USD
Jan 1, 2023
30,500.00 USD
Jan 1, 2024
141,500.00 USD
The ETHZilla Interest Expense history
YEARInterest ExpenseYoY
141,500.00USD+363.93%
30,500.00USD-99.80%
15.12 MUSD-410.85%
-4.86 MUSD+67.52%
-2.90 MUSD-311.16%
1.37 MUSD-33.02%
2.05 MUSD+209.62%
663,000.00USD—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

ETHZilla Stock analysis

What does ETHZilla do? 180 Life Sciences Corp. develops pharmaceuticals for chronic pain and inflammatory diseases, focusing on three research programs: Fibrosis and Anti-TNF, SCAs, and a7nAChR. The Fibrosis and Anti-TNF program targets conditions such as Dupuytren’s contracture, frozen shoulder, polycystic ovarian disease (POCD), and nonalcoholic steatohepatitis (NASH). The SCAs program addresses chronic pain and early arthritis, while the a7nAChR program focuses on smoking cessation and ulcerative colitis. The company generates revenue through the development and potential future sale of these pharmaceutical products, targeting patients and healthcare providers in the treatment of inflammatory and chronic pain conditions. The company operates as a research and development firm with a pipeline of drugs in separate areas of inflammation. Its products are designed to treat specific diseases within inflammation, including Dupuytren’s contracture, frozen shoulder, POCD, NASH, chronic pain, early arthritis, and ulcerative colitis. Revenue is derived from the commercialization of these pharmaceuticals once they reach the market, with no mention of current sales or partnerships in the business description. 180 Life Sciences Corp. is structured around three distinct drug development programs, each targeting a specific disease area. The Fibrosis and Anti-TNF program covers multiple inflammatory conditions, while SCAs and a7nAChR address chronic pain and smoking-related health issues, respectively. The company’s revenue model relies on the successful development and market entry of these pharmaceuticals, with no indication of current revenue streams beyond its R&D phase. ETHZilla is one of the most popular companies on Eulerpool.

Frequently Asked Questions about ETHZilla stock

Interest Expense of ETHZilla is 141,500.00 USD in 2024.

Interest Expense of ETHZilla changed from 30,500.00 USD to 141,500.00 USD, representing a 363.93% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of Interest Expense ETHZilla since 2006 – with annual values, charts, and detailed analysis.

Interest expense represents the cost of borrowing. Higher interest expenses can indicate a highly leveraged company.

Interest Expense's USD is a key factor for investors. Changes in this metric can signal improving or deteriorating fundamentals, directly impacting the stock price. On Eulerpool, you can track Interest Expense's ETHZilla historically and in real time.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Income Statement — ETHZilla

All Key Metrics — ETHZilla